Real-World Assessment of Ritlecitinib in Patients with Severe Alopecia Areata: A 24-Week Multicentre Retrospective Study

    July 2025 in “ Clinical and Experimental Dermatology ”
    Luca Valtellini, Gianluca Avallone, Giulia Murgia … Silvia Mariel Ferrucci
    Studysummary This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    2. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    3. Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review Clinical and Experimental Dermatology · 2024

    Related research 4

    1. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    2. Linear Alopecia Areata JAAD case reports · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    4. Overview of Alopecia Areata ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2013